R L Koretz. Show Affiliations »
Abstract
Mesh: See more » AdultAgedAntiviral Agents/therapeutic useCost-Benefit AnalysisDrug CostsHepatitis C, Chronic/therapyHumansInterferon alpha-2Interferon-alpha/economicsInterferon-alpha/therapeutic useLife ExpectancyMaleRecombinant ProteinsTreatment Outcome
Substances: See more » Antiviral AgentsInterferon alpha-2Interferon-alphaRecombinant Proteins
Year: 1998 PMID: 9786731 DOI: 10.1016/s0016-5085(98)70284-7
Source DB: PubMed Journal: Gastroenterology ISSN: 0016-5085 Impact factor: 22.682